Summary
This content was automatically synthesized by Credo's AI models directly from the original source text.
AI summaries can make mistakes — double-check important details against the original source.
1 Sample Definition And Size
The study was a nationwide cohort study in Sweden including 2,480,797 singleton liveborn children born between July 1, 1995, and December 31, 2019, with follow-up through December 31, 2021. Among these, 185,909 children (7.49%) were exposed to acetaminophen during pregnancy. A sibling control analysis included 1,773,747 full siblings. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38592388/?utm_source=openai))
2 Study Type
Population-based prospective cohort study with sibling control (matched full-sibling) analysis using stratified Cox regression to control for familial confounding. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38592388/?utm_source=openai))
3 Conflicts Of Interest
One author disclosed ties to Neobiomics AB; another disclosed ties to law firms and AlphaSights. ([healthday.com](https://www.healthday.com/healthpro-news/child-health/acetaminophen-use-during-pregnancy-not-linked-to-neurodevelopmental-disorders?utm_source=openai))
4 Results Summary
In conventional models without sibling control, acetaminophen use during pregnancy was associated with marginally increased risks: autism (HR 1.05, 95% CI 1.02–1.08; risk difference at 10 years 0.09%, 95% CI –0.01% to 0.20%), ADHD (HR 1.07, 95% CI 1.05–1.10; RD 0.21%, 95% CI 0.08%–0.34%), and intellectual disability (HR 1.05, 95% CI 1.00–1.10; RD 0.04%, 95% CI –0.04% to 0.12%). In sibling control analyses, there was no association: autism (HR 0.98, 95% CI 0.93–1.04), ADHD (HR 0.98, 95% CI 0.94–1.02), intellectual disability (HR 1.01, 95% CI 0.92–1.10). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38592388/?utm_source=openai))